Allied Biotech Corporation (TPEX:1780)
Taiwan · Delayed Price · Currency is TWD 24.80
+0.30 (1.22%)
Sep 8, 2026, 1:24 PM CST
Allied Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 922.49 | 849.51 | 806.92 | 720.43 | 716.75 | 676.76 | |
Revenue Growth | 14.67% | 5.28% | 12.01% | 0.51% | 5.91% | 9.50% |
Cost of Revenue | 566.25 | 540.9 | 548.53 | 473.99 | 445.7 | 418.71 |
Gross Profit | 356.24 | 308.61 | 258.38 | 246.44 | 271.05 | 258.05 |
Selling, General & Admin | 192.97 | 159.79 | 144.15 | 131.64 | 144.71 | 120.64 |
Research & Development | 28.77 | 28.43 | 26.12 | 26.09 | 24.56 | 25.74 |
Operating Expenses | 221.38 | 188.27 | 170.27 | 157.73 | 171.27 | 146.38 |
Operating Income | 134.87 | 120.34 | 88.12 | 88.71 | 99.78 | 111.67 |
Interest Expense | -14.92 | -17.32 | -13.96 | -12.96 | -11.75 | -11.25 |
Interest & Investment Income | 16.25 | 22.5 | 24.67 | 15.63 | 5.3 | 1.65 |
Currency Exchange Gain (Loss) | 93.48 | 36.22 | 30.92 | 29.88 | 88.11 | -85.55 |
Other Non Operating Income (Expenses) | 1.85 | 3.24 | 0.29 | 1.12 | 5.01 | 1.06 |
EBT Excluding Unusual Items | 231.54 | 164.98 | 130.04 | 122.38 | 186.45 | 17.58 |
Gain (Loss) on Sale of Assets | 0.06 | -0.86 | - | - | -1.59 | - |
Other Unusual Items | - | - | - | - | 0.17 | - |
Pretax Income | 231.6 | 164.12 | 130.04 | 122.38 | 185.04 | 17.58 |
Income Tax Expense | 51.07 | 34.67 | 29.1 | 24.97 | 38.29 | 4.54 |
Net Income | 180.52 | 129.46 | 100.94 | 97.41 | 146.74 | 13.04 |
Net Income to Common | 180.52 | 129.46 | 100.94 | 97.41 | 146.74 | 13.04 |
Net Income Growth | 270.24% | 28.25% | 3.62% | -33.62% | 1025.14% | -83.59% |
Shares Outstanding (Basic) | 97 | 96 | 96 | 96 | 95 | 95 |
Shares Outstanding (Diluted) | 97 | 96 | 96 | 96 | 96 | 95 |
Shares Change | 0.71% | 0.10% | 0.37% | 0.20% | 0.43% | 0.05% |
EPS (Basic) | 1.86 | 1.35 | 1.05 | 1.02 | 1.54 | 0.14 |
EPS (Diluted) | 1.86 | 1.34 | 1.05 | 1.01 | 1.53 | 0.14 |
EPS Growth | 265.78% | 27.62% | 3.96% | -33.99% | 1018.40% | -83.52% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 223.47 | 183.55 | 196.98 | 89.71 | 109.62 | 22.44 |
Free Cash Flow Per Share | 2.30 | 1.90 | 2.04 | 0.94 | 1.14 | 0.23 |
Dividend Per Share | 1.250 | 1.250 | 1.000 | 0.850 | 1.200 | 0.500 |
Dividend Growth | 25.00% | 25.00% | 17.65% | -29.17% | 140.00% | -37.50% |
Gross Margin | 38.62% | 36.33% | 32.02% | 34.21% | 37.82% | 38.13% |
Operating Margin | 14.62% | 14.16% | 10.92% | 12.31% | 13.92% | 16.50% |
Profit Margin | 19.57% | 15.24% | 12.51% | 13.52% | 20.47% | 1.93% |
Free Cash Flow Margin | 24.22% | 21.61% | 24.41% | 12.45% | 15.29% | 3.32% |
EBITDA | 190.42 | 175.73 | 144.33 | 152.38 | 165.12 | 170.53 |
EBITDA Margin | 20.64% | 20.69% | 17.89% | 21.15% | 23.04% | 25.20% |
D&A For EBITDA | 55.55 | 55.39 | 56.21 | 63.67 | 65.34 | 58.86 |
EBIT | 134.87 | 120.34 | 88.12 | 88.71 | 99.78 | 111.67 |
EBIT Margin | 14.62% | 14.16% | 10.92% | 12.31% | 13.92% | 16.50% |
Effective Tax Rate | 22.05% | 21.12% | 22.38% | 20.41% | 20.70% | 25.81% |